全球联合抗体治疗市场,按类型(抗体/抗体、抗体-药物偶联物、双特异性抗体、化疗-单克隆抗体、其他)、适应症(癌症、艾滋病毒、其他)、给药途径(口服、肠胃外、其他)、最终用户(医院、家庭护理、专科中心、其他)、分销渠道(医院药房、网上药房、零售药房)划分 – 行业趋势和预测到 2029 年。
联合抗体治疗市场分析及规模
预计全球联合抗体治疗市场将在 2022 年至 2029 年的预测期内出现显著增长。由于持续关注开发副作用较少的靶向癌症疗法,全球联合抗体治疗市场在过去几年中经历了革命性的发展。因此,与干扰细胞分裂过程并杀死体内快速分裂细胞并在此过程中杀死健康细胞的传统细胞毒性化学疗法不同,联合抗体等靶向疗法被发现更有效。
Data Bridge Market Research 分析了 2022-2029 年预测期内全球联合抗体治疗市场的增长率。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外,Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。
市场定义
联合抗体治疗市场范围和细分
报告指标 |
细节 |
预测期 |
2022 至 2029 年 |
基准年 |
2021 |
历史岁月 |
2020(可定制为 2014 - 2019) |
定量单位 |
收入(百万美元)、销量(单位)、定价(美元) |
涵盖的领域 |
类型(抗体/抗体、抗体-药物偶联物、双特异性抗体、化疗-单克隆抗体、其他)、适应症(癌症、艾滋病毒、其他)、给药途径(口服、肠胃外、其他)、最终用户(医院、家庭护理、专科中心、其他)、分销渠道(医院药房、网上药房、零售药房) |
覆盖国家 |
北美洲的美国、加拿大和墨西哥、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、巴西、阿根廷和南美洲其他地区 |
涵盖的市场参与者 |
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd (Israel), Seagen Inc. (U.S.), CELGENE CORPORATION (U.S.), Genmab A/S (Denmark) |
Market Opportunities |
|
Market Definition
Monoclonal antibody drugs are treatments that enlist your body's germ-fighting immune system against diseases, including cancer. Targeted cancer therapies fight cancer cells with more precision, attacking only the molecules that are essential for tumor growth and progression, and leading to potentially lesser side effects.
Global Combination Antibody Therapy Market Dynamics
Drivers
- Increase in Cancer Cases
The increase in cancer cases worldwide boosts the global small cell lung cancer (SCLC) therapeutics market in the forecast period. According to the reports of the American Cancer Society Statistics in 2016, majority of cases of SCLC mostly occur in individuals between the age group of 60-80 years with a projected global death rate being 30,000 each year. In addition to this, as per the reports of WHO, lung cancer is the second most dominant cancer in men and women leading to 1.59 million deaths in 2012. This boost the market growth.
- Development of Diversified Treatments
Treatments such as phage or yeast display, and transgenic mice, for human monoclonal antibodies generation and also employment of advanced genetic engineering technology offer great benefits to the patients. Thus, it boosts the market growth.
Opportunities
- Patent Expiration Encourages New Launches
Patent expiration of several old companies can make better opportunities for the new market players. Adopting combination therapies is a significant factor contributing to the growth of the monoclonal antibodies market. Additionally, increased R&D fundings are an add-on to the market.
- Growing research activities
There has been increased research activities that are creating more opportunities for the market growth. For instance, in 2008, U.S. based company Biogen Inc. announced the successful phase III clinical trials of Rituxan. In combination with chemotherapy, this drug helped improve progression free survival in patients with relapsed chronic Lymphocytic Leukemia. In 2010, the FDA approved Rituxan in combination with chemotherapy drugs such as fladarabinie and cyclophosphamide (FC) for the treatment of the most common type of Adult Leukemia. This creates more opportunity in the market.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained healthcare professionals who are unaware of the knowledge of the treatment methods for this disease could limit the growth of the global combination antibody therapy market during the forecast period.
- Increasing Cost Of Treatments
The huge expenditure required for the treatment methods hamper the market growth. Many of the treatments involved in this disease demand high cost and thus at times, it gets difficult for many people, particularly the ones in the rural areas. Thus, this can act as a major hindrance factor for the market.
This global combination antibody therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global combination antibody therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Combination Antibody Therapy Market Scope
The global combination antibody therapy market is segmented on the basis of type, indication, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Antibody/Antibody
- Antibody-Drug Conjugates
- Bispecific Antibodies
- Chemotherapy-Monoclonal Antibodies
- Others
Indication
- Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Blood Cancer
- HIV
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Combination Antibody Therapy Market Regional Analysis/Insights
The global combination antibody therapy market is analyzed and market size insights and trends are provided by type, indication, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global combination antibody therapy market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to have the highest market growth due to increased prevalence of cancer and related disorders and number of generic drugs.
North America dominates the market due to focus of global market players and novel technologies.
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外,在提供国家数据预测分析时,还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
竞争格局和全球联合抗体治疗市场份额分析
全球联合抗体治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对全球联合抗体治疗市场的关注有关。
全球联合抗体治疗市场的主要参与者包括:
- F. Hoffmann-La Roche Ltd.(瑞士)
- Mylan NV(美国)
- 赛诺菲(法国)
- 辉瑞公司(美国)
- 葛兰素史克公司 (英国)
- 诺华公司(瑞士)
- 拜耳公司(德国)
- 礼来(美国)
- 默克公司(美国)
- 太阳制药工业有限公司 (印度)
- Aurobindo Pharma(印度)
- 梯瓦制药工业有限公司 (以色列)
- Seagen Inc.(美国)
- CELGENE 公司(美国)
- Genmab A/S(丹麦)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.